The Radiopharmaceutical Industry in Morocco: An Analytical Overview of Constraints and Developmental Prospects

Abstract

The Moroccan radiopharmaceutical industry is currently under development. The country has two operational cyclotrons capable of producing fluorine-18-labeled radiopharmaceuticals (RPs), primarily for PET imaging, while all other therapeutic and SPECT-dedicated RPs are imported. Importation processes are administratively complex and subject to fluctuations in global supply chains. The RP industry also faces additional challenges, including a stringent regulatory framework, limited accessibility, reimbursement barriers, and a scarcity of trained professionals in radiopharmacy and nuclear medicine more broadly. Furthermore, limited education and awareness among referring clinicians hinder the integration of some nuclear medicine procedures into routine clinical practice. Despite these challenges, Morocco has significant potential for localized RP production. Strategic investment and partnerships with key international agencies could enhance radiopharmacy infrastructure, streamline regulatory pathways for local manufacturing, and foster the development of new training programs for professionals in Morocco and other African countries.